Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069040 | 0.87 | P2RX7 (0.50) | F2P2RX7TNKSNPSR1CYP3A4 | |
| SCHEMBL11515844 | 0.86 | F2 (0.40) | F2NPSR1CYP3A4CYP2C9PKM | |
| SCHEMBL11515849 | 0.86 | F2 (0.40) | F2NPSR1CYP3A4CYP2C9PKM | |
| SCHEMBL30439075 | 0.86 | P2RX7 (0.49) | F2P2RX7TNKSNPSR1CYP3A4 | |
| SCHEMBL464681 | 0.85 | PREP (0.55) | F2P2RX7NPSR1FAPDPP4 | |
| SCHEMBL4330609 | 0.84 | FAP (0.41) | F2NPSR1CYP3A4CYP2C9PKM | |
| SCHEMBL4327210 | 0.84 | FAP (0.41) | F2NPSR1CYP3A4CYP2C9PKM | |
| SCHEMBL1046070 | 0.83 | DPP4 (0.46) | F2NPSR1FAPDPP4PREP | |
| SCHEMBL1046072 | 0.83 | DPP4 (0.46) | F2NPSR1FAPDPP4PREP | |
| SCHEMBL5178008 | 0.82 | DPP4 (0.48) | F2FAPDPP4PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777876-B1 | N-ACYLDIPEPTIDE DERIVATIVES AND THEIR USES | NEOSTRATA COMPANY INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20190111132-A1 | PHOTOREACTIVE COLLAGEN-LIKE PEPTIDES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111132-A1 | PHOTOREACTIVE COLLAGEN-LIKE PEPTIDES | COL14A1, COL1A1, COL2A1 | F2 134/4885P2RX7 3012/4885TNKS 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.